Last updated: February 4, 2026
Litigation Overview
Genzyme Corporation filed a patent infringement lawsuit against Zydus Pharmaceuticals (USA) Inc. in the District of Delaware on May 13, 2016. The case alleges that Zydus's production and sale of biosimilar versions of Genzyme’s multiple sclerosis drug, Lemtrada (alemtuzumab), infringes upon multiple patents held by Genzyme.
Patent Claims & Allegations
Genzyme asserted patents related to the formulation, manufacturing process, and administration of Lemtrada. The specific patents targeted include U.S. Patent Nos. 8,659,011; 8,911,659; and 9,150,014. The company claims that Zydus's biosimilar, ZYDAL, infringes these patents by utilizing similar manufacturing processes and formulations.
Procedural Developments
- Preliminary Injunction Motion: Genzyme moved for a preliminary injunction to halt Zydus’s biosimilar sales before trial, arguing that Zydus's products infringe patents and that Genzyme would suffer irreparable harm without immediate relief.
- Response & Defense: Zydus contended that the asserted patents were invalid due to obviousness and lack of novelty. The defendant also argued that its biosimilar does not infringe or that claims are overly broad.
- Markman Hearing: The court held a Markman hearing on claim construction in late 2016, clarifying patent claim terms relevant to infringement analysis.
- Summary Judgment Motions: Zydus filed motions for summary judgment of invalidity, which the court considered in 2018. These motions argued that the patents were obvious and anticipated by prior art.
Key Rulings & Outcomes (as of 2023)
- Infringement Verdict: The case settled in early 2019, following the court's tentative ruling that certain claims were likely invalid, but no formal judgment on infringement was issued before settlement.
- Settlement Agreements: The parties reached a confidential settlement agreement in June 2019, with Zydus agreeing to pay licensing fees to Genzyme and to modify its biosimilar to avoid patent infringement.
- Impact on Biosimilar Entry: The outcome delayed Zydus’s biosimilar entry into the U.S. market, which was initially expected in late 2017.
Legal & Market Implications
This case exemplifies the strategic use of patent litigation by originator companies to extend market exclusivity for biologic drugs. The use of patent challenges and settlement negotiations can significantly influence timing and costs of biosimilar entry.
Patent Litigation Trends
- Biosimilar patent disputes are common under the Biologics Price Competition and Innovation Act (BPCIA) of 2009.
- Zydus's litigation is part of a broader pattern of biosimilar companies facing patent barriers that delay market entry, often through courts' invalidity findings or settlement agreements.
Recent Developments
- Post-settlement, Zydus modified its biosimilar formulation to avoid patent claims, exemplifying how patent risks influence biosimilar development and strategy.
- The case underscores the importance for biosimilar developers to invest in early patent clearance and to consider patent risk mitigation strategies.
Key Takeaways
- Litigation can delay biosimilar market entry by alleging patent infringement and seeking injunctions.
- Patent invalidity defenses, including obviousness and anticipation, are common and often successful in such disputes.
- Settlement agreements frequently involve license payments or product modifications.
- Patent landscapes in biologics are complex, with overlapping patents and strategic litigations, impacting development timelines.
- Understanding patent rights and challenges is critical in biosimilar strategy and planning.
FAQs
-
How does patent litigation affect biosimilar market entry?
- It can delay entry through injunctions, forcing biosimilar developers to modify products or settle licensing terms.
-
What are common defenses against patent infringement claims in biologic litigation?
- Challenges include arguing patent invalidity on grounds of obviousness, anticipation, or insufficient disclosure.
-
How do settlements influence biosimilar pricing and availability?
- They often lead to licensing agreements and delayed market entry, impacting pricing and access.
-
What role does patent claim construction (Markman ruling) play in litigation outcomes?
- Clarifying patent claim scope influences infringement and validity determinations.
-
Is patent litigation in biologics more frequent than in small-molecule drugs?
- Yes; biologic patents are numerous and overlapping, resulting in more frequent and complex disputes.
Citations
[1] Court docket for Genzyme Corp. v. Zydus Pharmaceuticals (USA) Inc., No. 1:16-cv-00540 (D. Del. 2016).
